The 7500 represents a fresh look at Broad Ion Beam Milling. The system is designed around our new 50 cm plasma source and a new high reliability rotary substrate table. The ion source is the ...

Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 data in hand, Beam has established clinical proof-of ...

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...